NCT03166306View on ClinicalTrials.gov

Angiogenic Imaging in Pulmonary Arterial Hypertension

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

October 31, 2019

Study Completion Date

March 31, 2020

Conditions
Pulmonary Arterial HypertensionExercise Associated Pulmonary Arterial Hypertension
Interventions
DIAGNOSTIC_TEST

PET-CT Imaging with [89Zr]-bevacizumab

Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.

Trial Locations (1)

02115

Brigham and Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT03166306 - Angiogenic Imaging in Pulmonary Arterial Hypertension | Biotech Hunter | Biotech Hunter